Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
NCT00064714 on ClinicalTrials.gov · last registry update 2015-03-11
A small phase 2 — 47 participants, against a typical 110. The sponsor logged completion for March 2008. Primary outcome, as filed: Change in basal C-peptide level. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 47
- Started
- 2003-07
- Primary completion
- 2008-03 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in basal C-peptide level
Conditions studied
Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.